Corona Remedies Limited has announced the availability of the audio recording from its analyst and investor conference call discussing the company's Q2 FY26 financial results. The pharmaceutical company made this disclosure to both BSE Limited and the National Stock Exchange of India Limited on January 5, 2026.

Regulatory Compliance and Disclosure

The company has fulfilled its regulatory obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 by making the earnings call audio accessible to stakeholders. This disclosure follows the company's earlier communication dated December 30, 2025, ensuring transparency in financial reporting processes.

Accessibility and Stakeholder Information

The audio recording of the conference call has been made available on the company's official website for easy access by analysts, investors, and other stakeholders. The recording covers discussions on the company's unaudited financial results for both the second quarter and half year periods ended September 30, 2025.

The disclosure was signed by Chetna Dharajiya, who serves as the Company Secretary and Compliance Officer for Corona Remedies Limited. The company trades on BSE Limited under scrip code 544644 and on the National Stock Exchange of India Limited under the symbol CORONA.

Corona Remedies Limited has filed its unaudited financial results for the second quarter and half-year ended September 30, 2025, with stock exchanges under Regulation 33 of SEBI Listing Regulations. The Board of Directors approved these results at their meeting held on January 2, 2026, demonstrating strong operational performance across key financial metrics.

Strong Q2FY26 Financial Performance

The pharmaceutical company delivered impressive consolidated results for Q2FY26, with revenue from operations reaching ₹360.00 crores, representing robust 20.0% year-on-year growth. Net profit after tax surged 21.4% to ₹52.20 crores, showcasing the company's operational efficiency and strong market positioning.

Half-Year Performance Highlights

For the half-year period H1FY26, Corona Remedies maintained strong momentum with revenue from operations growing 17.0% year-on-year to ₹707.67 crores. Profit after tax increased significantly by 35.1% to ₹98.52 crores, reflecting improved operational leverage and enhanced profitability across business segments.

Key Financial Ratios and Metrics

Corona Remedies demonstrated strong return ratios for H1FY26 with annualized Return on Equity at 31.1% and Return on Capital Employed at 49.7%. The company maintained efficient working capital management with net working capital days at 23 days and operating cash flow to EBITDA ratio at 76.5%.

Management Commentary and Outlook

Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, highlighted the company's outperformance against Indian Pharmaceutical Market growth. He emphasized the consistency of strategy, disciplined execution, and focus on core therapeutic segments including strengthening field force, expanding brand portfolio, and maintaining focus on specialist prescriptions.

Earnings Call Announcement

Corona Remedies will conduct an earnings call on January 5, 2026, at 12:00 PM IST to discuss the financial and business performance for Q2FY26. The company has provided multiple dial-in numbers for domestic and international participants to facilitate comprehensive investor engagement.

Company Profile and Operations

Founded in 2004, Corona Remedies operates WHO-GMP and EU GMP-certified manufacturing facilities with two DSIR-approved R&D centers employing over 4,500 people. The company focuses on multiple therapeutic areas including women's healthcare, cardio-diabeto, pain management, and urology. Corona Remedies completed its Initial Public Offering and listed on NSE and BSE on December 15, 2025.